No Data
US Stock MarketDetailed Quotes
ADCT ADC Therapeutics
Watchlist
0.770
+0.040+5.48% Trading 11/29 14:46 ET
0.794High0.688Low164.36KVolume
0.725Open0.730Pre Close121.37KTurnover0.33%Turnover RatioLossP/E (TTM)62.09MMarket Cap5.75052wk HighLossP/E (Static)80.64MShares0.36052wk Low-1.15P/B38.76MFloat Cap56.590Historical High--Dividend TTM50.34MShs Float0.360Historical Low--Div YieldTTM14.51%Amplitude0.738Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About ADC Therapeutics Company
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
Revenue Breakdown
Business
Unit:USD
2022/12/31
Stock NameRevenueRatio
Single segment209.91M100.00%
News
Analyst Expectations for ADC Therapeutics's Future
Within the last quarter, ADC Therapeutics (NYSE:ADCT) has observed the following analyst ratings: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings22000Last 30D100001M Ago010002M
HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Lowers Price Target to $3
HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $12 to $3.
Sobi to Present New Data at ASH 2023 Annual Meeting
Sobi will present new data at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego from the 9th to the 12th of December...
Comments
ColumnsADC Therapeutics | LOTIS-9 Combo Study Takes a Breather on Enrollment
ADCT before market open today announced its voluntary pause in the enrollment of the LOTIS-9 combo trial of Zynlonta and Rituxan (Lonca-R) in front-line unfit/frail DLBCL. We also caught up with the mgmt team this morning for more insights. Briefly, the pause was driven by higher-than-expected respiratory-related TEAEs (incl. 7 Gr 5, 5 Gr 3/4) after a recent data review of 40 pts. Of the 12 TEAEs, 1 Gr 5 case was deemed to be r...
$ADC Therapeutics(ADCT.US$ big space to rebound.
$ADC Therapeutics(ADCT.US$ good news🔥
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--